['rheumatoid arthritis']
['sarilumab sar153191 (regn88)', 'methotrexate', 'folic acid']

        Inclusion criteria:

          -  Diagnosis of RA, according to the American College of Rheumatology/The European League
             Against Rheumatism (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria with
             >=3 months disease duration.

          -  Moderately to severely active RA defined as:

          -  At least 8 of 68 tender joints and 6 of 66 swollen joints at screening visit.

          -  High sensitivity C-Reactive Protein (hs-CRP) >=6mg/L at screening visit.

        Exclusion criteria:

          -  Participants <20 or >75 years of age.

          -  Treatment with any Disease-modifying antirheumatic drug (DMARD) other than MTX or
             biologic agent without the appropriate off-drug period prior to screening.

          -  Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor
             (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      